Drug Profile
Sucroferric oxyhydroxide - CSL Vifor
Alternative Names: Ferric oxyhydroxide; Ferrihydrite; Iron oxyhydroxide; P-TOL; PA-21; PA21-1; Phosphate binder - CSL Vifor ; suroferric oxyhydroxide; VelphoroLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Vifor Pharma
- Developer CSL Vifor; Fresenius Medical Care; Kissei Pharmaceutical; Vifor Fresenius Medical Care Renal Pharma
- Class Ferric compounds; Hyperphosphataemia therapies
- Mechanism of Action Phosphate binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperphosphataemia
Most Recent Events
- 23 Aug 2022 CSL Vifor has patent protection for Velphoro (sucroferric oxyhydroxide) in USA
- 23 Aug 2022 US District Court for the District of Delaware issued a judgment in Vifor Fresenius Medical Care Renal Pharma’s (VFMCRP) favour
- 02 Aug 2022 Vifor Pharma has been acquired by CSL and renamed to CSL Vifor